Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Swine Flu Media Bulletin Issued At: 11am Friday 12 June 2009, Wales
Spread and extent of the outbreak (information as at 5pm on 11 June)
generic viagra online
White House Reform Chief Was On Boards Of Health Companies With Suspect Practices
Before taking her job as the White House health reform director, Nancy-Ann DeParle earned more than $6 million serving on the boards of major health care corporations, some of which were accused of fraud, mismanagement and regulatory violations during her tenure, the Investigative Reporting Workshop at American University reports on MSNBC.com. Some critics say the corporate relationships could be a conflict of interest for DeParle. Also, while there"s no evidence DeParle was involved in or aware of allegedly fraudulent activities, in three cases, she served on board committees overseeing the companies" legal and regulatory compliance.
News of the day
MitraClip(R) Therapy Data Demonstrate Clinical Benefit In High-Risk Patients With Mitral Regurgitation
Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation (FMR) or degenerative mitral regurgitation (DMR) improves patient clinical status. The results from the 78 patient EVEREST II High Risk Registry demonstrated improvement in left ventricular function and reduced hospitalization for congestive heart failure for both MR groups at twelve months. Additionally, a reduction in mortality compared to the predicted mortality risk of surgery was reported for the registry. The results of the High-Risk Registry were presented at the third annual meeting of EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Nutrition

PharmaCom BioVet, Inc. Begins To Review The Process To Potentially Receive Minor Use/Minor Species Drug Approval From FDA

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that the Company has begun the process to potentially apply and endeavor to receive a Minor Use/Minor Species (MUMS) drug approval from the Federal Drug Administration (FDA). Meeting the MUMS requirement is part of the New Drug Approval Process if the Company decides to potentially run clinical trials on a histone deacetylase inhibitor for canines with hemangiosarcoma, which the Corporation is considering the development of. The histone deacetylase inhibitor would be directed for dogs suffering from an acute type of cancer, canine hemangiosarcoma. The Minor Use and Minor Species Animal Health Act became law in 2004. Minor uses are based on there being a small number of animals eligible for treatment with the product in question for the specific intended use. Small numbers have been determined for each of the 7 major species (cows, horses, pigs, chickens, turkeys, dogs, and cats). These have been published in a proposed rule (http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-5385.pdf). To determine if a use is minor, the standard is that the intended use is for a "small number of animals." There is a different "small number" for each of the 7 major species and it reflects the number of animals affected by the disease over a one-year period. "We are continuing to review the FDA filing requirements in order to determine if we may meet the requirements stated by the MUMS Act. By doing so, we potentially progress closer to being able to begin the testing of a novel cancer treatment for canines with Hemangiosarcoma," stated Gary S. Berthold, President of PharmaCom BioVet, Inc. PharmaCom BioVet, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009